title: [Effect of KLF6 on prostate cancer cell line PC-3 by transgenic method].
abstract: OBJECTIVE
  To observe the effect of KLF6 on prostate cancer cell line PC-3 by transgenic method.
  
  
  METHODS
  We obtained KLF6 cDNA by RT-PCR method from the liver cell, transfected plasmid pEGFP-C, recombinated with KLF6 into PC-3 cells, and used them as a transfection group and a control group. MTT, flow cytometer and immunocytochemical methods were used to observe the effect of anti-oncogene wild type KLF6 on prostate cancer cell line PC-3 by transgenic method for 48 hours.
  
  
  RESULTS
  After transfected into PC-3 cells, KLF6 enhanced growth suppression, (30.0 +/- 5.4)% in the transfection group and 0% in the control, P < 0.01, apoptosis, (24.3 +/- 2.3)% in the transfection group and (5.2 +/- 0.7)% in the control, P < 0.01, the down-regulation of the expression of cyclin D1, (25.3 +/- 3.7)% in the transfection group and (38.5 +/- 4.6)% in the control, P < 0.05 and Bcl-2, (18.7 +/- 3.2)% in the transfection group, and (41.8 +/- 5.9)% in the control, P < 0.01 in PC-3 cells. It also decreased the ratio of the cell phase G2/M, increased the ratio of G0/G1 from (58.6 +/- 7.3)% in the control to (80.0 +/- 9.8)% in the transfection group, P < 0.05.
  
  
  CONCLUSIONS
  PC-3 cells transfected with wild type KLF6 can enhance its growth suppression and apoptosis. It shows great potential for the gene therapy of androgen-independent carcinoma of the prostate.
authors.affiliation: Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. sunming2003@163.com
authors.forename: Ming
authors.initials: M
authors.lastname: Sun
authors.forename: Yu-ru
authors.initials: YR
authors.lastname: Yang
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.forename: Yi-ping
authors.initials: YP
authors.lastname: Lu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wei
authors.forename: Tian-yong
authors.initials: TY
authors.lastname: Fan
authors.forename: Xiang
authors.initials: X
authors.lastname: Li
mesh_terms: D017209:Apoptosis / Q000502:physiology; D002453:Cell Cycle / Q000502:physiology; D045744:Cell Line, Tumor; D019938:Cyclin D1 / Q000096:biosynthesis; D015536:Down-Regulation; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D000075723:Kruppel-Like Factor 6; D051741:Kruppel-Like Transcription Factors / Q000235:genetics* / Q000502:physiology; D008297:Male; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000502:physiology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
chemical_list: C105465:KLF6 protein, human; D000075723:Kruppel-Like Factor 6; D051741:Kruppel-Like Transcription Factors; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D019938:Cyclin D1